LIFE News and Press, aTyr Pharma Inc. From 09/15/20

ATyr Pharma (NASDAQ: LIFE )   announced that its partner Kyorin Pharmaceutical, a wholly owned subsidiary of Kyorin Holdings has dosed the first subjects in a Phase 1 trial of aTyr’s lead therapeutic candidate ATYR1923. More news on: aTyr Pharma, Inc., Healthcare stocks news ...

SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholl...

Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and ind...

aTyr Pharma (NASDAQ: LIFE ) enters into a common stock purchase agreement providing for the sale of up to $20M of common stock to Aspire Capital Fund, LLC. More news on: aTyr Pharma, Inc., Healthcare stocks news, , Read more ...

Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months. SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on nove...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 08/7/2020. Please visit our Tracking Ole Andreas Halvorsen&...

SAN DIEGO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present at two investor conferences in Sept...

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (the “Company”) (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., ...

CureVac (NASDAQ: CVAC ) +47%  on making reasonable profit on COVID-19 vaccine. More news on: CureVac N.V., LMP Automotive Holdings, Inc., Microbot Medical Inc., Stocks on the move, , Read more ...

aTyr Pharma, Inc. (LIFE) Q2 2020 Earnings Conference Call August 13, 2020 05:00 p.m. ET Company Representatives Sanjay Shukla - President, Chief Executive Officer Jill Broadfoot - Chief Financial Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Hartaj Singh...